The 9MMNontuberculous Mycobacterial (NTM) Lung Disease Drug Treatment Market is expected to offer an $ opportunity of USD 17,546.2 Million over the analysis period. Market was estimated USD 8,325.7 Million during 2023 and expected to grow at a significant CAGR 4.6% over the projected period. And by the end of 2033, the market is expected to touch USD 25,648.4 Million.
Pipeline drugs expected to provide an opportunity of more than USD 6,834.2 Million during the forecast year.
Disease Overview: Nontuberculous mycobacteria (NTM) are organisms naturally occurred in water and soil. In few patients, the organism infects the airways and lung tissue resulting into disease. The majority of NTM lung cases in the developed country such as in United States is caused by Mycobacterium avium complex (MAC). Almost everyone comes in contact with NTM, however it usually only causes infection in people with underlying lung disease, such as bronchiectasis or COPD, a weakened immune system or older age or the previous history of lung infections. NTM disease is not contagious. Approximately more than 90K people are expected to be living with NTM lung disease in the United States as of 2023. After COVID-19 pandemic infection rate seems to be rising, particularly among women and older age people. Few common symptoms of NTM lung disease are chronic cough, fatigue, weight loss, fever and night sweats. Read more….
Report has deeply investigated patient’s presentation and tailored treatment
Report has Covered Granular-level Analysis in Each Mapped Market
Nontuberculous Mycobacterial (NTM) Lung Disease Disease Burden Analysis: (Result shown here is reflecting from meta-analysis, and CSP Analytics Solutions Analysis)
This section explored the epidemiology associated with Nontuberculous Mycobacterial (NTM) Lung Disease across regions
Experts indicated prevalence increased significantly across regions, but gaps in estimates still persist.
Our research report has provided crystal clear view of prevalent pool across regions. Since epidemiology estimation accompanied with lot of complexity, our report has streamlined the estimation process for enhancing market understanding.
Report has also highlighted, impact of improvements in diagnosis, on diagnosis rate (%).
The treatment of Nontuberculous Mycobacterial (NTM) needed multidisciplinary and patient-centered regime based on quality-of-life and patient benefits rather than to eradicate mycobacterial infection exclusively. Pulmonary NTM infection comparable from a TB lung infection in which it does not needed instant initiation of treatment upon diagnosis but should be expected within a considerable timeframe to halt disease progression. Treatment generally relays on combination of two to three antibiotics for six months to a year or longer depending on severity of infections. Not all patients with NTM lung disease require urgent treatment, but they should assess and monitor by a specialist familiar with the condition (one who has managed patients with this disease before).
Antibiotics generally prescribed to treat NTM lung disease. Successful treatment can take 1.5 yrs to 2 yrs. Some people will make a full recovery, while others need ongoing monitoring for the rest of their life.
Proper diagnosis is necessary to diagnose, how and where NTM exposure happened (for example, a contaminated spa bath) to curtail the risk of further infections.
This report section deals with the treatment strategies adopted by healthcare professional while dealing across patients’ segments. Also provided gaps in current treatment and upcoming treatment options.
The treatment of Nontuberculous Mycobacterial (NTM) Lung Disease typically involves the use of Macrolides, Rifamycins, Aminoglycosides, and Others.
Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease’s requires holistic framework to address diverse set of patients. Collaboration among various specialties is imperative to devise tailoring treatment plan. Efforts to encourage diagnosis rate and advocacy at patient and physician level is crucial to provide better therapeutic options.
Report section covers detailed around various types of available treatments
Macrolides
Rifamycins
Aminoglycosides
Others
Also covers patient segment targeted by each therapy type: This section address concerns regarding unaddressed patient pool
Several companies and institutions collaborating to bring out the appropriate treatment solutions
Our report analysis revealed that, there are tremendous opportunities exits in the market in order to close the current market gaps
Recent clinical guidelines enable the streamlining the treatment approaches
Report has examined the how many and what type of cases refer to which type of therapy based on experts’ opinion analysis.
Rising incidence of chronic respiratory conditions, especially Chronic Obstructive Pulmonary Disease (COPD), is a prominent driver. COPD patients can compromise lung function and attack immunity, making patients more vulnerable to NTM infections. Newley diagnosed population is aspiring for advanced treatment, since market is deprived of better therapy and accompanied with huge unfulfilled market unmet need. The dearth of curative option and the potential for disease recurrence highlight the demand for more effective, targeted and tolerable treatment options.
Untreated Prevalent Pool of Nontuberculous Mycobacterial (NTM) Lung Disease
Huge medical unmet need:
Advancements in diagnosis tools
Advancements in Treatment Options
Proliferation of novel treatment options
Advent of emerging therapy for developing tailoring treatment
Emergence of Targeted Therapies
Market Challenges: Explored in the report
Limited Treatment Options
High Treatment Costs
Clinical Trial Enrollments
Access to Care and Treatment
Research and development gaps
Misdiagnosis and Underdiagnosis
Lack of adequate treatment compliance and adherence
Nontuberculous Mycobacterial (NTM) Lung DiseaseMapped Geography: Nine Major Markets (9MM)
Report has fragmented the total market into five regions such as:
United States
5-Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
China
Japan
India
RoW (Rest of World)
Each mapped region has been examined at granular level based on below parameters:
United States Nontuberculous Mycobacterial (NTM) Lung Disease Drug Treatment Market: The United States Nontuberculous Mycobacterial (NTM) Lung Disease drug treatment market is experiencing significant growth, driven by recent therapeutic advancements, increased disease awareness, and a rising patient population. Market Share of United States: As of 2023, the United States captured nearly ~43.7% market share. United States Nontuberculous Mycobacterial (NTM) Lung Disease Drug Treatment Market is also driven by FDA approval of novel therapies, advancements in diagnosis, rising awareness and health expenditure.
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Market Unmet Need Analysis
5-Europe Nontuberculous Mycobacterial (NTM) Lung Disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
By Country
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
China Nontuberculous Mycobacterial (NTM) Lung Disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
India Nontuberculous Mycobacterial (NTM) Lung Disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Japan Nontuberculous Mycobacterial (NTM) Lung Disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Rest of the World Nontuberculous Mycobacterial (NTM) Lung Disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Company Profiles:
Paratek Pharmaceuticals Inc.
Spero Therapeutics
Mannkind Corporation
AN2 Therapeutics, Inc.
Insmed Incorporated
Beyond Air Inc.
Savara Inc.
Vast Therapeutics
Renovion
RedHill Biopharma
Matinas BioPharma Holdings, Inc.
MicuRx Pharmaceuticals, Inc.
Others
Reason to buy this report:
Fostering Understanding on Nontuberculous Mycobacterial (NTM) Lung Disease Treatment Market
In Order to Understand the Market Potential
Opportunity Analysis (exist in the market for players)
